MORGAN STANLEY PLC/CALL/INCYTE CO./60/0.5/20.12.24 | Real-time Bid/Ask 18:08:51 23/05/2024 BST | ||
| 2.29 EUR / 2.4 EUR | +5.63% |
|
| Current month | +73.44% | ||
| 1 month | +48.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 2.41 | +8.56% |
| 22/05/24 | 2.22 | +0.45% |
| 21/05/24 | 2.21 | +6.25% |
| 20/05/24 | 2.08 | +14.92% |
| 17/05/24 | 1.81 | -6.22% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 02:13 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9H2Y |
| ISIN | DE000ME9H2Y1 |
| Date issued | 01/03/2024 |
| Strike | 60 $ |
| Maturity | 20/12/2024 (211 Days) |
| Parity | 2 : 1 |
| Emission price | 4.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.55 € |
|---|---|
| Lowest since issue | 1.14 € |
| Spread | 0.11 € |
| Spread % | 4.60% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
58.2
USD
Average target price
73.65
USD
Spread / Average Target
+26.54%
- Stock Market
- Warrants
- Warrant
